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Background: Beyond its classical role in calcium homoeostasis and bone metabolism, vitamin D deficiency has been
found to be associated with several diseases, including diabetes, non-alcoholic fatty liver disease, and even obesity
itself. Importantly, there are limited data on therapeutic strategies for vitamin D deficiency in bariatric patients, and
the procedure-specific guidelines may not be sufficient. To improve long-term outcomes, nutritional screening and
appropriate supplementation to prevent nutrient deficiencies are urgently needed. Therefore, the aim of this study is
to examine effects and safety of a forced dosing regimen of vitamin D versus conventional dose supplementation on
vitamin D levels and other parameters in bariatric patients.
Methods/Design: The study includes loading plus repeat dosing compared with repeated administration of vitamin D
without a loading dose, according to guidelines, in a prospective, double-blind, randomized controlled trial. Up to a
triple oral loading dose is given on day 1, then 2 and 4 weeks after surgery (100,000 IU dose each time), followed by
an oral maintenance dose (3420 IU/day). The control group (n = 25) will receive placebo, followed by administration of
a standard dose (3420 IU/day). We hypothesize that a significant increase in vitamin D levels will occur in patients in
the treatment group (n = 25) by 24 weeks after surgery. Further measurements are aimed at evaluating changes in
inflammation, bone turnover, insulin resistance, blood pressure, liver, mental health, and gut microbiota of patients
undergoing omega-loop gastric bypass surgery. Furthermore, possible associations between concentrations of vitamin
D, the involved enzymes, or vitamin D receptor in adipose and/or liver tissues will be determined.
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Discussion: To our knowledge, this trial is the first of its kind with this type of vitamin D supplementation in bariatric
patients. Its major strength is the design and implementation of evaluation of influencing factors such as liver function,
bone health, inflammation, insulin resistance, blood pressure, symptoms of depression, or microbiota. This alternative
vitamin D dosing regimen has the potential to be a safe, fast, evidence-based treatment of vitamin D deficiency in
bariatric patients. Owing to the increasing number of bariatric patients, it is also of interest to elucidate the link
between obesity and vitamin D.
Trial registration: ClinicalTrials.gov identifier: NCT02092376. Registered on 17 March 2014.
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Obesity is a global epidemic [1] that is associated with
various comorbidities. It is part of the definition of the
metabolic syndrome, including arterial hypertension
and disturbances in glucose and lipid metabolism, with
an inherent risk of development of cardiovascular dis-
ease [2, 3]. These associated issues and obesity itself
contribute to increased morbidity, mortality rates, and
health care costs [4, 5].
Weight reduction is not easy to achieve and maintain.
Consequently, many individuals, especially those with
comorbidities, are referred for bariatric weight loss
surgery as a way to treat obesity and (pre)diabetes success-
fully [6]. Bariatric surgery is associated with effective and
long-term weight loss in morbidly obese patients and
decreases overall mortality [7]. At present, there are three
categories of bariatric procedures: (1) purely gastric re-
striction (e.g., gastric banding); (2) gastric restriction with
some malabsorption, as represented by the Roux-en-Y
(RYGB) or omega-loop gastric bypass (OLGB), reducing
the intake and absorption of food [8]; and (3) gastric
restriction with significant intestinal malabsorption (e.g.,
biliopancreatic diversion) [9]. In general, the more com-
plex the procedure, the better are the results in terms of
weight loss [10]. Because of this situation and the fact that
obesity itself is often accompanied by nutritional deficien-
cies, bariatric patients often have perioperative nutrient
deficiencies [9, 11–18]. These deficiencies should be de-
tected and clinically addressed early to avoid postoperative
complications. To improve long-term outcomes following
bariatric surgery, nutritional screening and prescribing
appropriate supplementation to prevent nutrient deficien-
cies is recommended at an early stage in pre- and postop-
erative care owing to the malabsorption and insufficient
intake. Vitamin D deficiency is common following bariat-
ric surgery and has been reported to occur in 50–80 % of
bariatric patients [19–22]. There are limited data on how
best to treat low vitamin D status in bariatric patients.
Procedure-specific guidelines may not be helpful in daily
practice, and the updated guidelines have not been evalu-
ated yet [23].Recent studies have shown that vitamin D may have
an impact on the prevention of many diseases, including
autoimmune disorders, hypertension, cancers, diabetes
[3, 24–26], depression [27–29], and, even more theoret-
ically, probably obesity itself [30].
Obesity is frequently characterized by reduced vitamin
D bioavailability, insulin resistance, and a chronic in-
flammatory response. There is a relationship between
serum concentrations of 25-hydroxy-vitamin D (25-OHD)
and several circulating inflammatory markers in severely
obese individuals [31]. This observed relationship between
low vitamin D status and obesity may be caused by
mechanisms such as sequestration in adipose tissue. The
mechanisms underlying the inverse relationship between
obesity and vitamin D deficiency are largely unknown.
Low serum 25-OHD might contribute to obesity by affect-
ing lipogenesis and/or adipogenesis in the adipose tissue.
Interestingly, recent studies [32] suggest that the adipose
tissue could be a direct target of vitamin D and that the
hormone may modulate adipose tissue formation and
function [33–37].
Obesity has recently been associated with non-alcoholic
fatty liver disease (NAFLD). NAFLD comprises a disease
spectrum ranging from relatively benign hepatic steatosis
to more severe steatohepatitis, fibrosis, cirrhosis, and
ultimately liver cancer [38]. It has become the most com-
mon form of chronic liver disease in Western countries,
with a prevalence approaching 50 % of the population
(already 40 % in the European Union) [39, 40]. It is
estimated that NAFLD will be the number 1 indication for
liver transplants in the United States in 2020 [41].
Currently, surgical treatment of coexisting NAFLD in
morbidly obese patients is an evolving matter of debate
[42]. A few studies propose that low levels of vitamin D
may contribute to the development of NAFLD [43].
However, the mechanisms underlying the association of
vitamin D and NAFLD are not yet fully understood.
Recent animal studies have shown that vitamin D has
an important role in the regulation of oxidative stress,
the production of proinflammatory cytokines [44, 45],
hepatocyte apoptosis [46], and even liver fibrosis [47].
Fig. 1 Study design and assessment points
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of bariatric patients [48, 49], and up to 5 % of these
patients may have unsuspected cirrhosis [50–52]. Be-
cause NAFLD is associated with the presence of obes-
ity, glucose and/or lipid disturbances, and arterial
hypertension, it is now considered the hepatic manifest-
ation of the metabolic syndrome.
There are limited data on therapeutic strategies for
vitamin D deficiency in bariatric patients, and procedure-
specific guidelines may not be very helpful in daily clinical
practice. Nevertheless, in the 2013 clinical practice
guidelines [23], the American Association of Clinical
Endocrinologists, the Obesity Society and American
Society for Metabolic and Bariatric Surgery recommend a
vitamin D supplementation of at least 3000 IU per day
and to titrate to the therapeutic 25-OHD level of
>75 nmol/L. This recommendation outlines the best evi-
dence level (grade A) [23], which is based on a single
randomized controlled trial done in the United States
[53]. In that study, the authors attempted to find the opti-
mal vitamin D treatment dose after surgery. Patients who
had undergone RYGB were randomized to three doses of
cholecalciferol: 800 IU, 2000 IU, and 5000 IU per day. The
authors found that all groups had insufficient vitamin D
levels at baseline and after 12 months; sufficient vitamin D
concentrations were reached in only 44, 78, and 70 % of
the patients in the respective groups [53]. Thus, even with
very high-dose supplementation, it may be challenging to
achieve normal 25-OHD levels in bariatric patients [54].
Vitamin D has multiple physiological functions beyond
its classical role in calcium homoeostasis and bone
metabolism, and morbidly obese persons have an in-
creased risk for low circulating 25-OHD levels [55, 56]
owing to the storage of vitamin D in adipose tissue [55].
Therefore, randomized controlled trials with vitamin
D supplementation, such as the present study (Link
between Obesity And Vitamin D in bariatric patients
with omega-loop bypass surgery [LOAD]), are needed to
establish and further pursue evidence-based and poten-
tially optimal treatment regimens for the increasing
number patients with low vitamin D status following
bariatric surgery and to define more carefully the impact
of specific surgical factors on vitamin D status.
Methods/Design
Overview
This prospective, double-blind, randomized controlled inter-
vention trial includes administration of a vitamin D loading
dose and repeat doses in patients undergoing bariatric sur-
gery. A stratified randomization design is being used to ob-
tain comparable groups to ensure that baseline variables
(25-OHD, age, and sex) are evenly distributed between
groups. Subjects are randomly assigned to the intervention
or control group. In this study, 50 bariatric patients planningto undergo OLGB will be recruited. Over the first month
postoperatively (day 1–3, weeks 2 and 4), they will receive
the loading dose of vitamin D. Afterwards, the maintenance
dose will be given up to 24 weeks and until the follow-up
visit. An overview of the study design and the assessment
points is provided in Fig. 1. The study was approved by
the local ethics committee of the Medical University of
Vienna (reference number 1899/2013) by the Austrian
Competent Authority (reference number LCM-718280-
0001), and it complies with the Declaration of Helsinki
[57]. Furthermore, the protocol was registered at Clinical-
Trials.gov (identifier: NCT02092376) and EudraCT (identi-
fier: 2013-003546-16). The study methods are in accordance
with the 2010 Consolidated Standards of Reporting Trials
(CONSORT) Statement guidelines for reporting random-
ized trials [58].
Preevaluation
The methods in this study are built upon a cohort study in
which investigators evaluated inter alia the vitamin D status
of 50 morbidly obese patients who underwent OLGB [54].
The findings of the evaluation illustrated that 96 % had vita-
min D deficiency preoperatively and that, after non-
standardized vitamin D supplementation, 80 % still had
vitamin D deficiency 12 months postoperatively [54]. Add-
itionally, there is evidence that, despite forced vitamin D
Table 1 Inclusion and exclusion criteria
Inclusion Exclusion
Men and women ages
18–100 years
Another planned form of bariatric surgery
Planned OLGB Hypercalcemia (calcium >2.63 mmol/L)
or hypocalcemia (calcium <1.75 mmol/L)
25-OHD <75 nmol/L Renal insufficiency (creatinine >133 μmol/L
or GFR <50 ml/min)
BMI >40 or ≥35 kg/m2
with comorbidities
Primary hyperparathyroidism
Body weight <150 kg
(owing to limitation of
DEXA measurement)
Malignancy
Capability to consent Infection (e.g., HIV)
Medical conditions requiring daily calcium
supplements or antacid use
Known hypersensitivity to cholecalciferol
No capability to consent
Imprisoned persons
Abbreviations: BMI body mass index, DEXA dual-energy X-ray absorptiometry,
GFR glomerular filtration rate, 25-OHD 25-hydroxy-vitamin D, OLGB
omega-loop gastric bypass
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creased bone resorption [22, 59, 60]. It could be possible
that morbidly obese patients might need higher 25-OHD
levels to reduce the risk for developing metabolic bone dis-
ease, osteoporosis [61], or other associated disorders.
Study objectives
Primary outcome measures
The primary objective of the present study is to examine
whether administration of up to three oral loading doses
in the first month postoperatively (day 1 and at weeks 2
and 4), followed by an oral maintenance dose (interven-
tion group) in bariatric patients can significantly increase
25-OHD levels 24 weeks after surgery as compared with
a control group receiving placebo followed by the stand-
ard daily maintenance dose (control group).
Secondary outcome measures
In further measurements, changes in inflammation, bone
turnover, bone mineral density (BMD), insulin resist-
ance, blood pressure, body fat mass, stage of liver stiff-
ness and steatosis, and mental health (improvement of
depression) will be investigated. Furthermore, we will as-
sess the adipose depot vitamin D concentrations and ex-
pression of enzymes (25-hydroxylases such as CYP27A1,
CYP2R1, CYP2J2, CYP3A4, CYP2C11, and CYP27B1, as
well as 24-hydroxylase CYP24A1) and vitamin D recep-
tor in subcutaneous tissue (SAT), visceral adipose tissue
(VAT), and liver tissue samples collected during surgery.
Additionally, the liver tissue samples will be used in
addition to the prescribed study-related measures for a
histological examination as extended diagnostics for
NAFLD or non-alcoholic steatohepatitis and molecular
analysis to further evaluate disease specific mechanisms
[62, 63].
Recruitment and eligibility
We are recruiting bariatric patients planning to undergo
OLGB and who are in- and/or outpatients in the obesity
clinic at the Department of Internal Medicine III or the
Department of Surgery at Vienna General Hospital. The
inclusion and exclusion criteria are shown in Table 1.
Sample size calculation
The study is powered to detect differences among the
groups for 24-week serum 25-OHD levels. On basis of the
preevaluation (cohort study), the placebo group was con-
servatively estimated to have an average 24-week 25-OHD
level of 50 ± 30 nmol/L. For sample size calculation, the
difference in 25-OHD levels between groups will be con-
sidered. Given a clinically relevant difference of 30 nmol/L
and a standard deviation of 35 nmol/L of the differences,
a two-sided significance level of 0.05, a sample size of 22
per group is needed to reach 80 % statistical power.Because imputation for dropouts of 20 % may have some
inestimable effect on the assumed standard deviation of
the differences, the sample size is increased to 25 per
group. To reach this sample size, a total of 50 bariatric
patients in the study are needed. The primary endpoint will
be analyzed according to the intention-to-treat principle.
Randomization
Subjects are randomly assigned to the intervention or con-
trol group, stratified by 25-OHD, age, and sex using the
Randomizer for Clinical Trials 1.8.1 online tool [64]. Each
subject receives an appropriate randomization number.
Randomization is carried out after the patient has signed
the informed consent form and before undergoing bariat-
ric surgery, right before the baseline assessment. Alloca-
tion to the groups is performed with consecutively
numbered dark bottles containing either vitamin D3 (cho-
lecalciferol) or placebo (carrier oil). These allocation bot-
tles are labeled with the randomization number.
Intervention
Loading dose determination
A loading dose is an extent of drug or substance designed to
fill the central volume of distribution to a concentration that
matches the final plateau concentration achieved with the
maintenance dose. Consequently, this final plateau could be
achieved sooner than the four half-lives required if it is ad-
ministered only at the maintenance dose rate [65]. Accord-
ing to the current guidelines, a minimal daily vitamin D
supplementation of at least 3000 IU is recommended [23].
To prevent failure of the study due to an insufficient treat-
ment dose, we chose the maximum loading dose for which
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for vitamin D3 in the body is between 2 and 3 months
[66–68]. As a result, the loading dose can be calculated as
the cumulative maintenance dose that is planned to be given
through one functional half-life of vitamin D, as follows:
Loading dose ¼ daily maintenance dose of 3420 IUð Þ
 90 daysð Þ
¼ 307; 800 IU total loading doseð Þ
In previous studies, researchers used doses exceeding
this dosage, at 500,000 and 600,000 IU of cholecalciferol/
vitamin D3 in frail elderly patients, young patients, and
critically ill patients, without observing any adverse effects
(e.g., hypercalcemia) [66, 69, 70]. The total loading dose of
300,000 IU is given on the basis of the measured 25-OHD
blood levels and/or concentrations (except for the first
dose, given at day 1 after surgery, of 100,000 IU) up to a
maximum of 300,000 IU. To make the loading dose proto-
col safer, 100,000 IU of vitamin D is administered at one
time to allow clearance from the circulation between each
increment of the loading dose [71].
According to the European Food Safety Authority
(EFSA), the no observed adverse effect level was
established at 10,000 IU per day and the tolerable
upper intake level (UL) at 4000 IU per day (based on
induction of hypercalcemia as the indicator of tox-
icity) [72, 73]. The maintenance dose, given after the
loading dose, is 3420 IU per day, which is in accord-
ance with the EFSA panel guideline of a UL of
4000 IU per day [72]. Taken together, no harm or risk
is expected for patients in the intervention and pla-
cebo groups. Importantly, as a result, appropriate se-
lection of maintenance and loading doses can reduce
the need for follow-up monitoring of 25-OHD levels.
Intervention group
The oral loading dose of 300,000 IU cholecalciferol
(vitamin D3) is divided into three doses (100,000 IU
each) and is given on day 1 and at 2 and 4 weeks
postoperatively. The oral maintenance dose is given
up to 24 weeks and until the follow-up visit
(46 weeks). All patients in the intervention group re-
ceive the first loading dose. The second and third
doses are given based on the 25-OHD serum concen-
tration, which is assessed before administration. If the
25-OHD does not reach a level above 75 nmol/L, a
100,000 IU dose is again given, up to 300,000 IU in
total. After the last loading dose, a maintenance dose
of 3420 IU per day (approximately translating to 60
drops and 24,000 IU per week) should maintain the
high 25-OHD concentration, according to guidelines
(Fig. 2) [23].Placebo group
The carrier solution (medium-chain triglyceride oil
[MCT]), of the verum formulation (MCT + vitamin D) is
used in the placebo-only group. The placebo group is
treated exactly the same as the intervention group (Fig. 2).
Measurements
Patient history and dietary assessment data are documented
at baseline and collected four times. For all subjects, body
weight, body composition, and blood parameters are
assessed eight times. The liver function assessment is done
four times. Blood pressure, depression symptoms, BMD,
and total body fat mass are measured two times in all study
groups. The visit and assessment schedule are shown in
Fig. 3 and Table 1.
The measurements to be performed are described in
the subsections below and in Table 2.
History, blood pressure, and dietary assessment
1. Medical history, such as comorbidities, prescribed
medications, and demographics (marital status,
education, migration background, and career)
2. Blood pressure (mmHg)
3. Dietary assessment to provide information regarding
dietary vitamin D intake as follows:
a. 5-day food record: During the week before the
scheduled visit, patients should record their food
intake for 5 days. Data are analyzed using the
nutritional software nut.s, which is based on
Bundeslebensmittelschlüssel (Max Rubner-Institut;
http://www.bls.nvs2.de/).
b. Mediterranean Adherence Score: A brief, validated
questionnaire regarding adherence to the
Mediterranean diet results on a 14-point scale
[74]; the higher the score, the better the adher-
ence to the proposed dietAnthropometry
1. Weight (kg), measured with a calibrated scale
2. Height (cm), measured with a wall stadiometer
3. Waist circumference, measured with an inelastic tape
4. Body composition: fat-free mass, lean body mass,
total body water, and phase angle are assessed by
bioelectrical impedance analysis (BIA) [75], based on
the transfer of a low-voltage alternating current
through the body. This measurement captures the
voltage drop of the applied current and result in
measuring resistance and reactance. It is used
with height, weight, age, and sex in a number of
multiple regression relationships to calculate body
composition compartments [76]. A single
frequency BIA at 50 kHz and 0.8 mA (Biacorpus
Fig. 2 Dosing regimen. [25 - OHD 25-hydroxy vitamin D]
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Germany) is passed between electrodes (Bodystat,
Isle of Man, UK) placed on the dominant side
hand and foot with patients in the supine
position.Fig. 3 Flowchart. [BMD bone mineral density]Stage of liver stiffness and steatosis
Transient elastography FibroScan (Echosens, Paris, France)
with a controlled attenuation parameter (CAP™) will be
performed based on transmitting a vibration signal into the
liver and receiving the resulting shear wave, which depends
Table 2 Measurements at several time points
Name Screening Intervention Follow-up
Duration 12 months 6 months 6 months
Visits Time Surgery Days 1–3 Wk 2 Wk 4 Wk 8 Wk 12 Wk 16 Wk 20 Wk 24 Wk 48
Anamnesis Anamnesis X X X
Body weight X X X X X X X X X
Anthropometry X X X X X X X X
Dietary assessment, BDI X X X X X
Bone density DEXA X X X
Liver and microbiota FibroScan and CAPTM X X X X X
Stool samples X X X X X
Biopsies Liver, SAT, VAT X
Supplementation Loading dose X X X
Maintenance dose X X X X X X X
Blood parameter Vitamin D X X X X X X X X X
Biochemical X X X X X X X X X
Liver X X X X X
Inflammation X X X X X X X X X
Insulin resistance X X X X X X X X X
Bone turnover X X X X X
Abbreviations: BDI Beck Depression Inventory, CAP controlled attenuation parameter; DEXA dual-energy X-ray absorptiometry, SAT subcutaneous adipose tissue,
VAT visceral adipose tissue
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the liver at 3.5 MHz and detects liver steatosis.
Bone mineral density and total body fat mass
Dual-energy X-ray absorptiometry (DEXA) will be used to
measure bone mineral content, BMD, and percent body fat.
Laboratory parameters
1. Vitamin D status: 25-OHD (nmol/L), 1,25-dihydroxy
vitamin D (pg/ml)
2. Biochemical parameters: sodium (nmol/L),
potassium (nmol/L), chloride (nmol/L), calcium
(nmol/L), magnesium (nmol/L), iron (μg/dl), total
protein (g/L), albumin (g/L), triglyceride (mg/dl),
total cholesterol (mg/dl), high-density lipoprotein
(mg/dl), low-density lipoprotein (mg/dl), vitamin
B12 (pmol/L), folic acid (nmol/L), vitamin A (μmol/
L), vitamin E (μmol/L), ferritin (μg/L), transferrin
(mg/dl), and transferrin saturation (%)
3. Bone turnover markers: calcium (mmol/L),
osteocalcin (ng/ml), bone-specific alkaline phosphatase
(U/L), type I collagen cross-linked C-terminal telopep-
tide (ng/ml), anorganic phosphate (mmol/L), parathy-
roid hormone intact (pg/ml), and amino-terminal
propeptide of type I procollagen (ng/ml)
4. Inflammation markers: C-reactive protein (mg/dl)
and interleukin 6 (pg/ml)5. Insulin resistance markers: C-peptide (ng/ml), insulin
(μU/ml), blood glucose (mg/dl), and glycosylated
hemoglobin HbA1c (%)
6. Liver parameters: aspartate transaminase (U/L),
alanine transaminase (U/L), γ-glutamyl transpeptidase
(U/L), total alkaline phosphatase (U/L), and
cholinesterase (U/L)
7. Blood count
8. Coagulation: Normotest (%) (Technoclone, Vienna,
Austria), activated partial thromboplastin time (s),
and fibrinogen (mg/dl)
9. Protein electrophoresis: serum protein
electrophoresis, haptoglobin (mg/dl), and
α2-macroglobulin (mg/dl)
Depression symptoms
The Beck Depression Inventory (BDI) [77] (simplified BDI-
V), a 21-question, multiple-choice, self-report inventory will
be used for measuring the severity of depression [78].
Microbiota composition
Stool samples will be collected to evaluate changes in
the composition of intestinal microbiota resulting from
weight reduction and vitamin D supplementation.
Biopsy
For the purposes of describing adipose depot vitamin D
concentrations and expression of enzymes in SAT, visceral
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surgeon during surgery. Furthermore, liver tissue samples
are used, in addition to the prescribed study-related
measures, for histological examination as extended diag-
nostics. Samples are snap-frozen in isopentane and stored
in nitrogen tanks at −196 °C until assayed. Biopsies will be
performed as follows:
1. Adipose tissue: The SAT sample is extracted through
a linear incision in the abdominal wall with no
additional incision. The VAT sample is taken from
the greater omentum, coming off the transverse colon.
2. Liver tissue: Standard intraoperative wedge and
needle biopsies are collected during surgery.
Statistical analysis
Data exploration using descriptive statistical analysis and
inferential statistics (uni- and multivariate) will be
performed. The data will be described by frequencies or
percentages, means and standard deviations, medians and
confidence intervals, and graphics. For proofing of normal
distributions, visual inspection of histograms or box plots
will be used. Independent samples t tests, Mann–Whitney
U test or χ2 tests will be performed to compare groups.
Correlation coefficients will be used with respect to the sec-
ondary outcomes. Analysis of covariance will be used to
compare parameters at baseline and after the intervention
(postoperatively), as well as after the follow-up, between
intervention and control groups, adjusting for the baseline
value as a covariate. IBM SPSS Statistics for Windows ver-
sion 22 software (IBM, Armonk, NY, USA) will be used for
all statistical analyses. All tests are two-sided, and a p value
<0.05 is considered statistically significant.
Discussion
The major strengths of the proposed study are the pro-
spective, randomized, double-blind, placebo-controlled
design and the implementation of an independent evalu-
ation of outcome parameters. The expected result,
positive or negative, should provide an evidence-based
and potentially optimal treatment of vitamin D defi-
ciency following bariatric surgery and should define the
interactions of vitamin D and specific factors, such as
liver and bone health, inflammation, insulin resistance,
blood pressure, depression symptoms, microbiota, and
weight loss. Furthermore, as far as we know, the LOAD
study is one of the first trials with this type of vitamin D
supplementation in bariatric patients.
Some aspects of the study design, however, may deserve
a closer discussion. Why was an active treatment regime
after the loading dose chosen for the control group? From
an ethical point of view, and bearing in mind the import-
ance of vitamin D for bone metabolism, it would be
difficult not to provide these patients with vitamin Dsupplementation at all. Therefore, we decided to use the
placebo only for the loading dose (in the first postopera-
tive month) to compare this dosing regimen with the
usual supplementation. Indeed, with this study design, we
expect to treat and provide supplements to the patients
more effectively than in routine care.
The prospective benefit will have a positive impact on
vitamin D status and therefore on the well-being and
health-related quality of life, which has been described in
the literature [79–81]. A further question might be why a
supplementation regimen different from an established
treatment of vitamin D deficiency in bariatric patients was
chosen. In fact, from a methodological point of view, a con-
stant daily supplementation of vitamin D would be prefera-
ble. However, there is evidence in the literature that this
standard supplementation in bariatric patients is not suffi-
cient, and with this novel dosing regimen, the final vitamin
D plateau could be achieved earlier than the four half-lives
required when administered only at the maintenance dose
rate [65]. Another important point for the success of the
LOAD study is the compliance of the participants
regarding regular study visits. Hence, we are in close con-
tact with the participants, and they are receiving text mes-
sages before the scheduled appointment.
Finally, one might assume that the rather small sample
size of 50 bariatric patients in the proposed study might
be underpowered to detect a significant difference be-
tween groups. However, the study is powered to detect
differences between the groups for 24-week serum 25-
OHD levels, with a given clinically relevant difference of
30 nmol/L and a standard deviation of 35 nmol/L of the
differences. Thus, if high-dose supplementation with
vitamin D is indeed effective, a reduction of vitamin D
deficiency after 24 weeks would not be unrealistic.
In conclusion, this vitamin D supplementation regimen
has the potential to be a safe, orally available, cheap, and
evidence-based treatment of low vitamin D status follow-
ing bariatric surgery in this increasingly prevalent group,
and the study probably also is an opportunity to find an
association between obesity and vitamin D deficiency.Trial status
The LOAD study commenced recruitment in April
2014. Recruitment was completed in April 2015.
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